The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
This isn't a share for the impatient trader Kingalf. There are too many positive news stories coming down the pipeline making the risk of losing out high and the cost painful!
News of a new test e.g. colorectal or ALS could drop anytime.
January brings FY 23 preliminaries. Expect those to show reduced losses as CiRT and PSE revenues grow. Should also get updates on CiRT and PSE sales growth and that could well confirm a transformation to profit making later next year.
USA Medicare and Medicade reimbursement code for the PSE test goes live in Jan and should encourage a jump in PSE sales across the pond.
Lab upgrades are scheduled for completion in Jan. These are in anticipation of increased volumes of episwitch tests in the UK and the US.
The announcement of the UK prostate screening trial 'Transform' is due Q1 24. Participants and roles likely to confirms PSE as a strong candidate for a national prostate screening programme.
New agreements with BUPA should follow the CiRT reimbursement agreement. PSE a likely basis for such agreements.
All of the above would be considered as imminent positives in any market other than AIM.
I'm slowly accumulating as I see this pushing through 50p early '24 and above £1 by the end of the year. Of course should big Pharma fancy some inorganic growth OBD must be a candidate!
Makes 'a significant personal investment' in OBD.
This is the kind of endorsement I like to see.
Https://www.linkedin.com/posts/stefhamill_im-happy-to-share-that-i-have-been-working-activity-7129784314245861376-an7K?utm_source=share&utm_medium=member_android
@comical1
which news programme did that revelation about toilet literature appear on? were they seriously suggesting that a significant proportion of the male population is unaware that ******* blood is good reason for an urgent visit to your gp? a waste of all too limited nhs funding if you ask me.
besides, i cant see a few posters in toilets transforming obd's growth trajectory when we already have medicare, medicaid and bupa on board.
still, as precursor to the predictable negativity of your last two sentences it was an admirable. if entirely transparent, attempt at turd polishing.
at least you didn't mention the need for a nasdaq listing this time. :)
Hi GMS,
Can't say I noticed a particular uptick in volumes following the Jeffries Investor shindig. To be fair I wasn't paying great attention so something might have passed me by. Would be good if some II's were quietly accumulating though.
Looking forward to Q1 '24 as I expect many positives here starting with the year end results and updates on CiRT and PSE commercialisation. Steve Arrivo will be busy trying make a mark. We also have lab certification, new products arriving (colorectal test?) and probable announcement of participation in Transform and maybe some more deals with insurers (BUPA 2). PSE sales should get a nice boost when the US reimbursement code goes live in January. Don't see the SP down here very long and I've been gradually accumulating since it dropped back into the '20's.
The company has been developing its senior management team (and its capabilities) and at the same time it has been expanding lab capacity and recruiting staff in anticipation of greater demand for testing.
Growth at this rate suggests high confidence in the ongoing commercialisation campaigns for both CiRT and PSE. A company going places.
I agree Chaps. It is early days, however if I was facing a biopsy I'd buy one in the blink of an eye. I don't expect the numbers to be huge at this stage but if we are managing a handful (single figures) of sales per day a profit margin of circa £500 per sale makes a significant contribution towards the company covering operating losses. Hopefully CiRT sales still on an upward trajectory too! Fingers crossed and GLA.
The January update should be a belter. It's not often companies talk about accelerating product development and commercialisation (PSE) due to 'unprecedented demand' (April RNS) that became 'overwhelming demand' in the May RNS. Couple that potential with the rapid increase in CiRT sales and the boost to those from the BUPA deal and the current SP looks extremely cheap.
Yep 5085.
Notice issued 30th November confirming medicare and Medicaid charge code for Episwitch PSE from Jan 1st.
For those interested in incorporating into your lottery numbers the code is 0433U. I'll just top up my holding as its more likely to pay out.
Just don't get the obsession with Diggle. Last time I looked he had bought more than he has sold in 2023. The recent selling has been a small fraction of his very
considerable holding and was most probably a compliance issue with Vulpes risk management to keep total value of holding below limits.
Sounds like a smart move.
https://thebusinessmagazine.co.uk/corporate-finance/spirent-communications-announces-series-of-strategic-business-moves/
4 spectacular RNS's in 3 months. Company appointing senior marketing personnel and bolstering lab infrastructure and staffing. Yet you would think nothing is happening here. Typical AIM traders.
January brings half yearly update including news on CiRT and PSE sales. Likely to signal a transformation of corporate finances to profit making. Potential for deals with US hospital groups or announcement of new tests that could drop anytime. A bit of patience would serve some well. It's only newspapers that provide daily news.
@Steve.
John Burrows explains how OBD exploits this type of database from about 8min 40 sec into the presentation below.
With the Medicare and Medicaid dedicated reimbursement code live in just a few weeks I wonder if we'll get a Dec Santa Rally here?
https://youtu.be/tv1zufLgtQM?si=t7q5IUEpBiX5MJYM